非小细胞肺癌的热点讨论医学课件.ppt

易瑞沙上市前后韩国晚期NSCLC患者的生存差异 1999.1-2001.12 易瑞沙上市前 (n=334) 二线治疗仅有化疗 实际临床实践中既往接受过化疗的 局部晚期/转移性NSCLC (韩国回顾性) 总生存期 Kim HS, et al. Oncolgy 2009; 76:239-246. 2002.1-2005.12 易瑞沙上市后 (n=334) 二线的新选择－－易瑞沙 易瑞沙上市前后两组韩国的NSCLC患者基线特征均衡 易瑞沙上市前 (n=334) 易瑞沙上市后 (n=334) 中位年龄 (岁) 58.0 59.0 男性 (%) 69.5 69.5 腺癌 (%) 66.5 66.5 ECOG PS 0-1 (%) 80.5 85.9 不吸烟 (%) 39.5 39.2 IIIB (%) 22.8 19.2 既往1-2 个化疗方案 86.2 87.7 既往3个以上化疗方案 13.8 12.3 Kim HS, et al. Oncolgy 2009; 76:239-246. 易瑞沙的上市显著延长了韩国NSCLC患者的总生存期 易瑞沙 上市前 上市后 MST (月) 11.5 19.3 1YS (%) 48.5 69.7 2YS (%) 19.3 39.6 Kim HS, et al. Oncolgy 2009; 76:239-246. 易瑞沙上市后 (n=334) 易瑞沙上市前 (n=334) 生存概率 (%) (月) p0.001 7.8月 21.2% 20.3% 易瑞沙的上市使韩国腺癌患者的总生存期得到显著的延长，中位生存超过2年 中位生存期 (月) HR=0.50 95 CI:0.41-0.61 P0.001 HR=0.89 95 CI:0.52-1.56 P=0.109 易瑞沙上市后，腺癌患者的总生存期 显著?1.22倍 Kim HS, et al. Oncolgy 2009; 76:239-246. 易瑞沙使中国的NSCLC患者获得长期生存 -----打破化疗时代的肺癌生存纪录 吴一龙等, 中华结核和呼吸杂志 2007; 30(2):98-102. 廖美琳等，肿瘤 2008; 28(3):246-250. 管忠震等，中华肿瘤杂志 2009; 31(2):148-151. 亚裔人群的突变率 亚裔晚期肺腺癌患者EGFR突变分子流行病学的前瞻性研究 (PIONEER) Pan-Chyr Yang,1 Shi Yuankai,2 Joseph Siu-Kie Au,3 Sankar Srinivasan,4 Gerardo Cornelio,5 Chun-Ming Tsai,6 Sumitra Thongprasert,7 Karin Heeroma,8 Itoh Yohji,9 Mai Trong Khoa10  1Department of Internal Medicine, National Taiwan University College of Medicine, National Taiwan University, Taipei, Taiwan; 2Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; 3Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong; 4Apollo Speciality Hospital, Anna Salai, Chennai, India; 5St. Peregrine Oncology Unit, San Juan De Dios Hospital, Pasay City, Philippines; 6Chest Department, Taipei Veteran’s General Hospital, Taipei, Taiwan; 7Department of Medicine, Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University, Chiang Mai, Thailand; 8AstraZeneca, Singapore; 9AstraZeneca, Osaka, Japan; 10Nuclear Medicine and Oncology Center, Bach Mai Hospital, Hanoi, Vietnam